{"id":"https://openalex.org/W2036254652","doi":"https://doi.org/10.1097/00001756-199612200-00002","title":"Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine","display_name":"Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine","publication_year":1996,"publication_date":"1996-12-01","ids":{"openalex":"https://openalex.org/W2036254652","doi":"https://doi.org/10.1097/00001756-199612200-00002","mag":"2036254652","pmid":"https://pubmed.ncbi.nlm.nih.gov/9051742"},"language":"en","primary_location":{"id":"doi:10.1097/00001756-199612200-00002","doi":"https://doi.org/10.1097/00001756-199612200-00002","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001756-199612200-00002","pdf_url":null,"source":{"id":"https://openalex.org/S121278948","display_name":"Neuroreport","issn_l":"0959-4965","issn":["0959-4965","1473-558X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NeuroReport","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103446078","display_name":"Richard B. Rothman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard B. Rothman","raw_affiliation_strings":["Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, MD 21224, USA","Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, MD 21224, USA","institution_ids":["https://openalex.org/I1327069482"]},{"raw_affiliation_string":"Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047863021","display_name":"MARIO A. AYESTAS","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Ayestas","raw_affiliation_strings":["Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004773599","display_name":"Michael H. Baumann","orcid":"https://orcid.org/0000-0001-7758-1470","observed_orcids":["https://orcid.org/0000-0001-7758-1470"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael H. Baumann","raw_affiliation_strings":["Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Psychopharmacology Section, DIR, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.9448,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.71631508,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"8","issue":"1","first_page":"7","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/phentermine","display_name":"phentermine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cocaine","display_name":"cocaine","score":0.9760000109672546},{"id":"https://openalex.org/keywords/mesolimbic-dopamine-system","display_name":"mesolimbic dopamine system","score":0.9869999885559082},{"id":"https://openalex.org/keywords/nucleus-accumbens","display_name":"nucleus accumbens","score":0.9490000009536743},{"id":"https://openalex.org/keywords/dopaminergic-neurotransmission","display_name":"dopamine signaling","score":0.6679999828338623},{"id":"https://openalex.org/keywords/cocaine-dependence","display_name":"cocaine dependence","score":0.6039999723434448},{"id":"https://openalex.org/keywords/fenfluramine","display_name":"fenfluramine","score":0.7799999713897705},{"id":"https://openalex.org/keywords/serotonin","display_name":"serotonin","score":0.652999997138977},{"id":"https://openalex.org/keywords/subjective-effects-of-cocaine","display_name":"subjective effects of cocaine","score":0.8159999847412109},{"id":"https://openalex.org/keywords/cocaine-challenge","display_name":"cocaine challenge","score":0.3199999928474426}],"concepts":[{"id":"https://openalex.org/C2778456266","wikidata":"https://www.wikidata.org/wiki/Q418157","display_name":"Phentermine","level":4,"score":0.9574538469314575},{"id":"https://openalex.org/C50156730","wikidata":"https://www.wikidata.org/wiki/Q3856966","display_name":"Microdialysis","level":3,"score":0.8990575075149536},{"id":"https://openalex.org/C2776552330","wikidata":"https://www.wikidata.org/wiki/Q1476178","display_name":"Nucleus accumbens","level":3,"score":0.7194373607635498},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.6900991201400757},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5081362724304199},{"id":"https://openalex.org/C2775894120","wikidata":"https://www.wikidata.org/wiki/Q271663","display_name":"Catecholamine","level":2,"score":0.49395304918289185},{"id":"https://openalex.org/C2777369949","wikidata":"https://www.wikidata.org/wiki/Q567709","display_name":"Anorectic","level":3,"score":0.46399232745170593},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4626513421535492},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4472019076347351},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3382107615470886},{"id":"https://openalex.org/C3018685816","wikidata":"https://www.wikidata.org/wiki/Q213449","display_name":"Food intake","level":2,"score":0.10826513171195984},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.10491952300071716},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003042","descriptor_name":"Cocaine","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D003042","descriptor_name":"Cocaine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008032","descriptor_name":"Limbic System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008032","descriptor_name":"Limbic System","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009435","descriptor_name":"Synaptic Transmission","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009714","descriptor_name":"Nucleus Accumbens","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009714","descriptor_name":"Nucleus Accumbens","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010645","descriptor_name":"Phentermine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012701","descriptor_name":"Serotonin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017551","descriptor_name":"Microdialysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018765","descriptor_name":"Dopamine Uptake Inhibitors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018765","descriptor_name":"Dopamine Uptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00001756-199612200-00002","doi":"https://doi.org/10.1097/00001756-199612200-00002","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001756-199612200-00002","pdf_url":null,"source":{"id":"https://openalex.org/S121278948","display_name":"Neuroreport","issn_l":"0959-4965","issn":["0959-4965","1473-558X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NeuroReport","raw_type":"journal-article"},{"id":"pmid:9051742","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9051742","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroreport","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1900035272","https://openalex.org/W2005239439","https://openalex.org/W2013737701","https://openalex.org/W2019908904","https://openalex.org/W2021830949","https://openalex.org/W2022114920","https://openalex.org/W2027580007","https://openalex.org/W2033192401","https://openalex.org/W2042328265","https://openalex.org/W2042625433","https://openalex.org/W2074494634","https://openalex.org/W2076776372","https://openalex.org/W2100782030","https://openalex.org/W2165398609"],"related_works":["https://openalex.org/W2008344720","https://openalex.org/W2007151271","https://openalex.org/W2028096169","https://openalex.org/W2046773943","https://openalex.org/W2002234714","https://openalex.org/W2145500736","https://openalex.org/W2063008351","https://openalex.org/W2021012195","https://openalex.org/W3175664622","https://openalex.org/W2922796154"],"abstract_inverted_index":{"Coadministration":[0],"of":[1,23,29,45,64,113,127],"phentermine":[2,40,73,96,121],"and":[3,78,95],"fenfluramine":[4],"has":[5],"been":[6],"used":[7],"to":[8,26],"treat":[9],"cocaine":[10,35,46,82,114,128],"dependence.":[11],"Patients":[12],"who":[13],"relapse":[14],"while":[15],"receiving":[16],"this":[17,52],"treatment":[18],"report":[19],"diminished":[20],"subjective":[21,125],"effects":[22,44,126],"cocaine.":[24],"Due":[25],"the":[27,43,61,100,110,124],"importance":[28],"mesolimbic":[30],"dopamine":[31],"(DA)":[32],"in":[33,56,60,93,103,129],"mediating":[34],"reinforcement,":[36],"we":[37],"hypothesized":[38],"that":[39,120],"might":[41],"attenuate":[42],"on":[47,115],"DA":[48,133],"transmission.":[49],"We":[50],"examined":[51],"proposal":[53],"directly":[54],"using":[55],"vivo":[57],"microdialysis":[58],"methods":[59],"nucleus":[62],"accumbens":[63],"awake":[65],"rats.":[66],"Rats":[67],"were":[68],"pretreated":[69],"with":[70,81],"saline":[71],"or":[72],"(1":[74],"mg":[75,84],"kg-1,":[76,85],"i.v.)":[77],"then":[79],"challenged":[80],"(3":[83],"i.v.).":[86],"Phentermine":[87,106],"alone":[88],"caused":[89],"a":[90,132],"modest":[91],"increase":[92],"DA,":[94],"pretreatment":[97],"substantially":[98],"reduced":[99],"cocaine-induced":[101],"rise":[102],"extracellular":[104],"DA.":[105],"did":[107],"not":[108],"alter":[109],"stimulatory":[111],"effect":[112],"5-HT.":[116],"Our":[117],"findings":[118],"suggest":[119],"may":[122],"antagonize":[123],"humans":[130],"via":[131],"mechanism.":[134]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}